The mineralocorticoid receptor in endothelial physiology and disease: Novel concepts in the understanding of erectile dysfunction

Massimiliano Caprio, Caterina Mammi, Iris Z. Jaffe, Maria Christina Zennaro, Antonio Aversa, Michael E. Mendelsohn, Andrea Fabbri, Giuseppe M C Rosano

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aldosterone is a steroid hormone that controls blood pressure by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor, and regulating genes that play a role in salt and water homeostasis in the kidney. Dysregulation of the mineralocorticoid system reveals its crucial role in various human diseases including hypertension, atherosclerosis, cardiac failure, mineralocorticoid resistance, and disorders of the nervous system. Recently, experimental animal models of mineralocorticoid/salt-induced hypertension and atherosclerosis have revealed an epithelial, pro-inflammatory role for MR activation. Extensive investigation has begun to elucidate the mechanisms underlying the vascular effects of MR activation which involve its direct role in cardiomyocytes, vascular smooth muscle cells, and endothelial cells. More specifically, in patients with cardiovascular risk factors and disease, including diabetes, hypertension, and/or congestive heart failure, an excess of MR activation has been shown to have a negative impact on endothelial function hence disrupting the physiological balance between vasoconstriction and vasodilation. Such a mechanism may play a role in the pathogenesis of erectile dysfunction. (ED), a condition that occurs frequently in patients with increased cardiovascular risk and involves endothelial dysregulation of vascular relaxation. The aim of this review is to summarize the latest concepts in MR signaling, with particular attention to the endothelium, and to discuss the potential benefits of tissue-selective MR blockade in treating subsets of ED patients, such as those with congestive heart failure and hypertension, in which the MR system may be over activated.

Original languageEnglish
Pages (from-to)3749-3757
Number of pages9
JournalCurrent Pharmaceutical Design
Volume14
Issue number35
DOIs
Publication statusPublished - 2008

Fingerprint

Mineralocorticoid Receptors
Erectile Dysfunction
Mineralocorticoids
Hypertension
Heart Failure
Blood Vessels
Atherosclerosis
Salts
Vasoconstriction
Nervous System Diseases
Aldosterone
Vascular Smooth Muscle
Cardiac Myocytes
Vasodilation
Smooth Muscle Myocytes
Endothelium
Homeostasis
Transcription Factors
Endothelial Cells
Animal Models

Keywords

  • Aldosterone
  • Endothelium
  • eNOS
  • Erectile dysfunction
  • Mineralocorticod receptor
  • RHO kinase
  • Vasoconstriction
  • Vasodilation

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

The mineralocorticoid receptor in endothelial physiology and disease : Novel concepts in the understanding of erectile dysfunction. / Caprio, Massimiliano; Mammi, Caterina; Jaffe, Iris Z.; Zennaro, Maria Christina; Aversa, Antonio; Mendelsohn, Michael E.; Fabbri, Andrea; Rosano, Giuseppe M C.

In: Current Pharmaceutical Design, Vol. 14, No. 35, 2008, p. 3749-3757.

Research output: Contribution to journalArticle

Caprio, Massimiliano ; Mammi, Caterina ; Jaffe, Iris Z. ; Zennaro, Maria Christina ; Aversa, Antonio ; Mendelsohn, Michael E. ; Fabbri, Andrea ; Rosano, Giuseppe M C. / The mineralocorticoid receptor in endothelial physiology and disease : Novel concepts in the understanding of erectile dysfunction. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 35. pp. 3749-3757.
@article{3e4ec1823041461e9f9cdcc69c887ef7,
title = "The mineralocorticoid receptor in endothelial physiology and disease: Novel concepts in the understanding of erectile dysfunction",
abstract = "Aldosterone is a steroid hormone that controls blood pressure by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor, and regulating genes that play a role in salt and water homeostasis in the kidney. Dysregulation of the mineralocorticoid system reveals its crucial role in various human diseases including hypertension, atherosclerosis, cardiac failure, mineralocorticoid resistance, and disorders of the nervous system. Recently, experimental animal models of mineralocorticoid/salt-induced hypertension and atherosclerosis have revealed an epithelial, pro-inflammatory role for MR activation. Extensive investigation has begun to elucidate the mechanisms underlying the vascular effects of MR activation which involve its direct role in cardiomyocytes, vascular smooth muscle cells, and endothelial cells. More specifically, in patients with cardiovascular risk factors and disease, including diabetes, hypertension, and/or congestive heart failure, an excess of MR activation has been shown to have a negative impact on endothelial function hence disrupting the physiological balance between vasoconstriction and vasodilation. Such a mechanism may play a role in the pathogenesis of erectile dysfunction. (ED), a condition that occurs frequently in patients with increased cardiovascular risk and involves endothelial dysregulation of vascular relaxation. The aim of this review is to summarize the latest concepts in MR signaling, with particular attention to the endothelium, and to discuss the potential benefits of tissue-selective MR blockade in treating subsets of ED patients, such as those with congestive heart failure and hypertension, in which the MR system may be over activated.",
keywords = "Aldosterone, Endothelium, eNOS, Erectile dysfunction, Mineralocorticod receptor, RHO kinase, Vasoconstriction, Vasodilation",
author = "Massimiliano Caprio and Caterina Mammi and Jaffe, {Iris Z.} and Zennaro, {Maria Christina} and Antonio Aversa and Mendelsohn, {Michael E.} and Andrea Fabbri and Rosano, {Giuseppe M C}",
year = "2008",
doi = "10.2174/138161208786898743",
language = "English",
volume = "14",
pages = "3749--3757",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "35",

}

TY - JOUR

T1 - The mineralocorticoid receptor in endothelial physiology and disease

T2 - Novel concepts in the understanding of erectile dysfunction

AU - Caprio, Massimiliano

AU - Mammi, Caterina

AU - Jaffe, Iris Z.

AU - Zennaro, Maria Christina

AU - Aversa, Antonio

AU - Mendelsohn, Michael E.

AU - Fabbri, Andrea

AU - Rosano, Giuseppe M C

PY - 2008

Y1 - 2008

N2 - Aldosterone is a steroid hormone that controls blood pressure by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor, and regulating genes that play a role in salt and water homeostasis in the kidney. Dysregulation of the mineralocorticoid system reveals its crucial role in various human diseases including hypertension, atherosclerosis, cardiac failure, mineralocorticoid resistance, and disorders of the nervous system. Recently, experimental animal models of mineralocorticoid/salt-induced hypertension and atherosclerosis have revealed an epithelial, pro-inflammatory role for MR activation. Extensive investigation has begun to elucidate the mechanisms underlying the vascular effects of MR activation which involve its direct role in cardiomyocytes, vascular smooth muscle cells, and endothelial cells. More specifically, in patients with cardiovascular risk factors and disease, including diabetes, hypertension, and/or congestive heart failure, an excess of MR activation has been shown to have a negative impact on endothelial function hence disrupting the physiological balance between vasoconstriction and vasodilation. Such a mechanism may play a role in the pathogenesis of erectile dysfunction. (ED), a condition that occurs frequently in patients with increased cardiovascular risk and involves endothelial dysregulation of vascular relaxation. The aim of this review is to summarize the latest concepts in MR signaling, with particular attention to the endothelium, and to discuss the potential benefits of tissue-selective MR blockade in treating subsets of ED patients, such as those with congestive heart failure and hypertension, in which the MR system may be over activated.

AB - Aldosterone is a steroid hormone that controls blood pressure by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor, and regulating genes that play a role in salt and water homeostasis in the kidney. Dysregulation of the mineralocorticoid system reveals its crucial role in various human diseases including hypertension, atherosclerosis, cardiac failure, mineralocorticoid resistance, and disorders of the nervous system. Recently, experimental animal models of mineralocorticoid/salt-induced hypertension and atherosclerosis have revealed an epithelial, pro-inflammatory role for MR activation. Extensive investigation has begun to elucidate the mechanisms underlying the vascular effects of MR activation which involve its direct role in cardiomyocytes, vascular smooth muscle cells, and endothelial cells. More specifically, in patients with cardiovascular risk factors and disease, including diabetes, hypertension, and/or congestive heart failure, an excess of MR activation has been shown to have a negative impact on endothelial function hence disrupting the physiological balance between vasoconstriction and vasodilation. Such a mechanism may play a role in the pathogenesis of erectile dysfunction. (ED), a condition that occurs frequently in patients with increased cardiovascular risk and involves endothelial dysregulation of vascular relaxation. The aim of this review is to summarize the latest concepts in MR signaling, with particular attention to the endothelium, and to discuss the potential benefits of tissue-selective MR blockade in treating subsets of ED patients, such as those with congestive heart failure and hypertension, in which the MR system may be over activated.

KW - Aldosterone

KW - Endothelium

KW - eNOS

KW - Erectile dysfunction

KW - Mineralocorticod receptor

KW - RHO kinase

KW - Vasoconstriction

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=61449213235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449213235&partnerID=8YFLogxK

U2 - 10.2174/138161208786898743

DO - 10.2174/138161208786898743

M3 - Article

C2 - 19128227

AN - SCOPUS:61449213235

VL - 14

SP - 3749

EP - 3757

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 35

ER -